{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:45:33Z","timestamp":1790300733592,"version":"4.1.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>A protracted epidemic of group B meningococcal disease in New Zealand led to the testing of a strain-specific tailor-made vaccine, MeNZB. Immunogenicity levels achieved during age group trials enabled New Zealand's regulatory authority to grant licensure to deliver MeNZB to all individuals under age 20. During the trials target strains for serum bactericidal antibody measurements included the vaccine target strain NZ98\/254 and two comparator epidemic-type strains (NZ94\/167 and NZ02\/09). In this study, 12 other strains differing variously from the vaccine strain by their capsular group, PorB type, and PorA variable region specificities, or PorA expression, were used as target strains. The PorA specificity of the serum bactericidal antibody responses to the vaccine was determined for 40 vaccinees. Sets of 10 pre- and postvaccination sera were chosen randomly from the young infant, older infant, toddler, and school-age group trials. Antibody recognition of linearized PorA proteins was also determined using immunoblotting. Across all age groups vaccine-induced serum bactericidal antibodies specifically targeted the VR2 P1.4 epitope of the PorA P1.7-2,4 protein irrespective of the PorB type and\/or capsular type of the target strain. Deletion of amino acids within the VR2 epitope or replacement of the epitope through genetic exchange allowed strains variously to resist antibody-directed complement-mediated lysis and negated PorA-specific antibody recognition in immunoblots. The demonstration that the immunodominant antibody response was specifically for the VR2 P1.4 epitope of the PorA protein supports the public health decision to use a strain-specific vaccine for the control of New Zealand's epidemic of meningococcal disease.<\/jats:p>","DOI":"10.1128\/cvi.13.4.486-491.2006","type":"journal-article","created":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T15:13:26Z","timestamp":1144422806000},"page":"486-491","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":95,"title":["The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZB"],"prefix":"10.1128","volume":"13","author":[{"given":"D. R.","family":"Martin","sequence":"first","affiliation":[{"name":"Institute of Environmental Science and Research (ESR), Porirua, New Zealand"},{"name":"New Zealand Ministry of Health, Wellington, New Zealand"},{"name":"Chiron Vaccines, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ruijne","sequence":"additional","affiliation":[{"name":"Institute of Environmental Science and Research (ESR), Porirua, New Zealand"},{"name":"New Zealand Ministry of Health, Wellington, New Zealand"},{"name":"Chiron Vaccines, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"McCallum","sequence":"additional","affiliation":[{"name":"Institute of Environmental Science and Research (ESR), Porirua, New Zealand"},{"name":"New Zealand Ministry of Health, Wellington, New Zealand"},{"name":"Chiron Vaccines, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"O'Hallahan","sequence":"additional","affiliation":[{"name":"Institute of Environmental Science and Research (ESR), Porirua, New Zealand"},{"name":"New Zealand Ministry of Health, Wellington, New Zealand"},{"name":"Chiron Vaccines, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Oster","sequence":"additional","affiliation":[{"name":"Institute of Environmental Science and Research (ESR), Porirua, New Zealand"},{"name":"New Zealand Ministry of Health, Wellington, New Zealand"},{"name":"Chiron Vaccines, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.2.832-837.2005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.vaccine.2005.01.050","volume":"23","year":"2005","unstructured":"Dyet, K., A. Devoy, R. McDowell, and D. Martin. 2005. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine23:2228-2230.","journal-title":"Vaccine"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S0950268805004954","volume":"134","year":"2006","unstructured":"Dyet, K., and D. Martin. 2006. Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic. Epidemiol. Infect.134:377-383.","journal-title":"Epidemiol. Infect."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/S0264-410X(03)00166-X","volume":"21","year":"2003","unstructured":"Gorla, M. C. O., A. P. S. Lemos, C. T. Saachi, J. C. de Moraes, and L. G. Milagres. 2003. Comparison of PorA VR types and porA promoter sequence from non-immunised children and vaccine failures immunized with a serogroup B outer membrane protein vaccine. Vaccine21:2871-2876.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","first-page":"6","volume":"7","year":"2003","unstructured":"Holst, J., I. S. Aaberge, P. Oster, D. Lennon, D. Martin, J. O'Hallahan, K. Nord, H. Nokelby, L. M. Naess, K. Moyner, P. Kristiansen, A. G. Skryten, K. Bryn, A. Aase, R. Rappuoli, and E. Rosenqvist. 2003. A \u2018tailor made\u2019 vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Eurosurveillance Wkly.7:6-9. [Online.] http:\/\/www.eurosurveillance.org\/ew\/2003\/030724.asp .","journal-title":"Eurosurveillance Wkly."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1099\/00222615-43-5-335","volume":"43","year":"1995","unstructured":"Idanpaan-Heikkila, I., E. A. Hoiby, P. Chattopadhyay, U. Airaksinen, T. M. Michaelsen, and E. Wedege. 1995. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J. Med. Microbiol.43:335-343.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","volume":"177","year":"1998","unstructured":"Martin, D. R., S. J. Walker, M. G. Baker, and D. R. Lennon. 1998. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis.177:497-500.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_9_2","unstructured":"Martin D. L. Lopez and R. McDowell. 2005. The epidemiology of meningococcal disease in New Zealand in 2004. A report to the Ministry of Health of New Zealand. Ministry of Health Wellington New Zealand. [Online.] http:\/\/www.moh.govt.nz\/moh.nsf\/0\/47914a3170b2449bcc2570290010e66c?OpenDocument\n."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.vaccine.2005.01.070","volume":"23","year":"2005","unstructured":"Martin, D., L. McCallum, A. Glennie, N. Ruijne, P. Blatchford, J. O'Hallahan, and P. Oster. 2005. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine23:2218-2221.","journal-title":"Vaccine"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0264-410X(00)00047-5","volume":"18","year":"2000","unstructured":"Martin, S. L., R. Borrow, P. van der Ley, M. Dawson, A. J. Fox, and K. A. V. Cartwright. 2000. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine18:2476-2481.","journal-title":"Vaccine"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/0140-6736(91)91297-8","volume":"337","year":"1991","unstructured":"McGuinness, B. T., I. N. Clarke, P. R. Lambden, A. K. Barlow, J. T. Poolman, D. M. Jones, and J. E. Heckels. 1991. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet337:514-517.","journal-title":"Lancet"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2958.1993.tb01141.x","volume":"7","year":"1993","unstructured":"McGuinness, B. T., P. R. Lambden, and J. E. Heckels. 1993. Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol. Microbiol.7:505-514.","journal-title":"Mol. Microbiol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.3.959-965.1998"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.vaccine.2005.01.061","volume":"23","year":"2005","unstructured":"O'Hallahan, J., D. Lennon, P. Oster, R. Lane, S. Reid, K. Mulholland, J. Stewart, L. Penney, T. Percival, and D. Martin. 2005. From secondary prevention to primary prevention\u2014a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine23:2197-2201.","journal-title":"Vaccine"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","year":"2005","unstructured":"Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZBTM: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23:2191-2196.","journal-title":"Vaccine"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/mpat.1993.1070","volume":"15","year":"1993","unstructured":"Rosenqvist, E., E. A. Hoiby, E. Wedege, D. A. Caugant, L. O. Froholm, B. T. McGuinness, J. Brooks, P. R. Lambden, and J. E. Heckels. 1993. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Microbiol. Pathog.15:197-205.","journal-title":"Microbiol. Pathog."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_19_2","first-page":"255","volume":"66","year":"2001","unstructured":"Rosenqvist, E., H. Kayhty, and A. J. Pollard. 2001. Determination of antibody responses to meningococcal antigens by ELISA, p. 255-273. In A. J. Pollard and M. C. J. Maiden (ed.), Methods in molecular medicine, vol. 66. Meningococcal vaccines: methods and protocols. Humana Press Inc., Totowa, N.J.","journal-title":"Methods in molecular medicine"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0264-410X(89)90194-1","volume":"7","year":"1989","unstructured":"Saukkonen, K., M. Leinonen, H. Abdillahi, and J. T. Poolman. 1989. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine7:325-328.","journal-title":"Vaccine"},{"key":"e_1_3_2_21_2","unstructured":"N. Z. Med. J. 2004 117"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1099\/13500872-142-1-63","volume":"142","year":"1996","unstructured":"Suker, J., I. M. Feavers, and M. C. J. Maiden. 1996. Monoclonal antibody recognition of members of the meningococcal P1.10 variable region family: implications for serological typing and vaccine design. Microbiology142:63-69.","journal-title":"Microbiology"},{"key":"e_1_3_2_23_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. H\u00f8iby, J. Holst, H. N\u00f8kleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_24_2","first-page":"6685","volume":"63","year":"2000","unstructured":"van der Ende, A., C. T. P. Hopman, and J. Dankert. 2000. Multiple mechanisms of phase variation of PorA in Neisseria meningitidis. Infect. Immun.63:6685-6690.","journal-title":"Infect. Immun."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/367899","volume":"187","year":"2003","unstructured":"van der Ende, A., C. T. P. Hopman, W. C. M. Keijers, L. Spanjaard, E. B. Lodder, and P. H. J. van Keulen. 2003. Outbreak of meningococcal disease caused by Por-A deficient meningococci. J. Infect. Dis.187:869-871.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.9.2963-2971.1991"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0264-410X(95)98264-B","volume":"13","year":"1995","unstructured":"van der Ley, P., J. van der Biezen, and J. T. Poolman. 1995. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the PorA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine13:401-407.","journal-title":"Vaccine"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.7.2745-2751.1996"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.4.1650-1655.2003"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1099\/00222615-38-1-23","volume":"38","year":"1993","unstructured":"Wedege, E., R. Dalseg, D. A. Caugant, J. T. Poolman, and L. O. Froholm. 1993. Expression of an incaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J. Med. Microbiol.38:23-28.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_31_2","first-page":"275","year":"2001","unstructured":"Wedege, E. 2001. Immunoblot analysis of sera from patients and vaccinees, p. 275-288. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal vaccines. Methods and protocols. Methods in molecular medicine. Humana Press Inc., Totowa, N.J.","journal-title":"Meningococcal vaccines"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.13.4.486-491.2006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.13.4.486-491.2006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:37:05Z","timestamp":1627591025000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.13.4.486-491.2006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1128\/CVI.13.4.486-491.2006"],"URL":"https:\/\/doi.org\/10.1128\/cvi.13.4.486-491.2006","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"2006-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}